Kornimate/medical-research-clean huggingface dataset:
risk factors of paraspinal muscles in degenerative lumbar spondylolisthesis

Conditions: Spine Degeneration

Summary: this is a retrospectively observational study. the goal of this observational study is to analyze the risk factors of paraspinal muscles associated with the occurrence of spondylolisthesis in patients with degenerative lumbar spondylolisthesis(dls) and to construct a predictive model. the main question it aims to answer is: which paraspinal muscle changes are risk factors for dls? we will collect the information of patients who have undergone lumbar mri in our hospital and have been diagnosed with back pain ( including spondylolisthesis or no spondylolisthesis) during the period from 2022 to 2024.the collected data included gender, age, body mass index (bmi), diabetes, hypertension, occupation and imaging parameters. we will then retrospectively analyze the risk factors associated with lumbar spondylolisthesis.


Eligibility criteria:
inclusion criteria: * patients who presented to our hospital with back pain(the diagnosis was spondylolisthesis or no spondylolisthesis); * patients older than 50 years; * patients with complete clinical data and magnetic resonance imaging (mri) before surgery. exclusion criteria: * the patient has previous spinal surgery; * patients with lumbar tumor,lumbar infection and lumbar tuberculosis; * patients with incomplete mri sequence.

Keywords: degenerative lumbar spondylolisthesis paraspinal muscles mri
the effect of adding pain relievers to local anesthesia before preforming drainage in peritonsillar abscess

Conditions: Peritonsillar Abscess

Summary: the purpose of this study is to find if adding oral pain relievers as dypiron and tramadol in addition to the local anesthesia injection, can help reducing the pain intensity in patients who diagnosed as suffering from peritonsillar abscess (pta)and treated by incision and drainage .

control group: the patient will get local anesthesia injection with lidocain. after 5 minutes- the dr will preform the incision and drainage of the abscess. then the patient will be asked by the vas score, the the pain intensity that he feels. intervention group:the patient will get dypiron 4 ml and tramadol 50 mg. after 40 minutes,the patient will get local anesthesia injection with lidocain. after 5 minutes- the dr will preform the incision and drainage of the abscess.then the patient will be asked by the vas score, the the pain intensity that he feels.

Eligibility criteria:
inclusion criteria:patients with pta in ages 18-65, who agreed to join the research - exclusion criteria:cave to dypiron and/or tramadol, pregnant women, mental illness,soldiers. -
feasibility and added value of the tracmotion device for esd

Conditions: Oesophageal Neoplasm

Summary: a single center non-randomized prospective clinical study, to evaluate the feasibility and added value of the ce-certified tracmotion device in patients scheduled consecutively for esd in the upper and lower gastrointestinal tract. after esd, the endoscopists' opinion will be evaluated with a short questionnaire on experience with the tracmotion device. the pathology report will be checked for radicality and microscopic damage of the removed lesion.

objective: the purpose of this study is to establish feasibility of the tracmotion device for esd and to define its added value during esd in both upper and lower gi procedures, both in antegrade and in retroflex positions. study design: single center prospective observational non-randomized clinical study. study population: a total of 20 consecutive cases scheduled for esd will be included. sample size calculation does not apply for this type of study. patients already scheduled for esd will undergo an esd procedure as planned with the aid of the tracmotion device. it is anticipated that the tracmotion will provide superior traction and counter traction compared to off-label tools. intervention: patients already scheduled for esd will undergo an esd procedure with the aid of the tracmotion device. main study parameters/endpoints: feasibility: procedure time, dissection speed, lesional damage (tearing or grasping injury to the mucosa on macroscopy and pathological review) added value: subjective evaluation of the tracmotion device by the performing endoscopist (contentment of use of tracmotion, difference in procedure time, stability of, control of and accessibility to the lesion).

Eligibility criteria:
inclusion criteria: * patients scheduled for endoscopic submucosal dissection (upper and lower gastrointestinal tract); * lesion is accessible with a therapeutic endoscope; * written informed consent; * age ≥18 years. exclusion criteria: * coagulopathy (not corrected prior to endoscopic submucosal dissection); * participating in a different experimental drug/device trial in the previous 3 months.
long-term neurocognitive sequelae of subclinical microembolization during carotid interventions

Conditions: Carotid Artery Stenosis

Summary: microembolization is commonly associated with carotid artery stenting (cas), but our understanding of subclinical microembolization is superficial. through collaborative effects of multidisciplinary team-experts, novel approaches, and longitudinal evaluations, we hope to better understand the clinical significance and long-term cognitive effects of microemboli. this proposal may change our current clinical practice by providing a better outcome measure for carotid interventions and improving outcomes of cas procedures through risk factor stratification. our central hypothesis is that development of subclinical microemboli is associated with decline in cognitive function following cas and that the risk of development of microemboli themselves is associated with patient- and procedure-related factors. we hope that this prospective study will help to clarify these important issues in the era of rapidly evolving percutaneous interventions.


Eligibility criteria:
inclusion criteria: * patient is male or female \>40 yrs of age. * patient has occlusive extracranial carotid stenosis (≥70%) * patient is scheduled to undergo an endovascular intervention of a lesion in the extracranial carotid artery * patient agrees to voluntarily participate and signs an informed consent. * patient agrees to be available for follow-up and is able to participate in all study testing procedures. * patient has sufficient visual and auditory acuity for cognitive testing. exclusion criteria: * patient is unable to safely and comfortably undergo magnetic resonance imaging procedures (e.g., claustrophobia, implanted medical devices that are mri incompatible such as pacemaker, defibrillator, neural stimulator etc) * patient has an untreated or unsuccessfully controlled psychiatric disease (schizophrenia, bipolar disorder). * patient has prominent suicidal or homicidal ideation. * patient has acute illness or unstable chronic illness (e.g. uncontrolled hypertension, hepatic encephalopathy, portal hypertension, ascites, and esophageal varices, pancreatitis). * patient with a history of neurological (e.g., multiple sclerosis, seizure disorder, parkinson's disease) or systemic illness affecting central nervous system function. * patient has prior closed head injury with ≥24 hours of amnesia. * patient is unable to understand or sign the informed consent.

Keywords: carotid artery stenting neuropsychological testing microembolization mri
early independent adaptive arm and hand rehab

Conditions: Post-stroke Hemiparesis

Summary: the purpose of this study is to test the hypothesis that early independent adaptive bimanual-to-unimanual training of arm and hand movements, assisted with specially designed mechanical devices: the mirrored motion bimanual arm trainer (m2 bat), will improve motor control and function in patients with post-stroke hemiparesis.

this study will randomly assign individuals admitted to the inpatient stroke rehabilitation unit to receive either conventional occupational therapy (ot) or conventional ot plus 1 hour additional bimanual-to-unimanual device-assisted therapy.

Eligibility criteria:
inclusion criteria: * ability to follow study instructions * ability to likely complete all required visits * ability to comply with the therapy protocol as assessed by the investigator * must be english speaking * subjects must have had a unilateral stroke exclusion criteria: * severe upper extremity spasticity suggested by an ashworth score of ≥3 at any joint, or restriction of full passive range of motion. * evidence of alcohol, drug abuse or other relevant neuropsychiatric condition such as psychotic illness or severe depression. * any condition or situation that, in the investigator's opinion, may put the subject at significant risk, confound the study results, or interfere significantly with the subject's participation in the study. * history of surgery or other significant injury to either upper extremity causing mechanical limitations that preclude task performance. * previous neurological illness such as head trauma, prior stroke, epilepsy, or demyelinating disease. * complicating medical problems such as uncontrolled hypertension, diabetes with signs of polyneuropathy, severe renal, cardiac or pulmonary disease, or evidence of other concurrent neurologic or orthopedic conditions precluding the subject from complying with the study protocol. * patients who are cognitively impaired. * patients who lack capacity to consent.

Keywords: motor control
a phase 4, conversion study of hectorol® injection to hectorol® capsules in stage 5 ckd patients on dialysis

Conditions: Secondary Hyperparathyroidism

Summary: hectorol is a safe and effective treatment of secondary hyperparathyroidism in hemodialysis patients. hectorol (doxercalciferol capsules) is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis and in pre-dialysis patients with stage 3 or stage 4 chronic kidney disease. hectorol (doxercalciferol injection) is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis. this protocol will determine clinically appropriate doses of hectorol (doxercalciferol capsules) when converting subject from hectorol (doxercalciferol injection.) the study will enroll hemodialysis patients that have been controlled on intravenous hectorol. the information gained from this study will be a useful guide for physicians in managing ckd stage 5 patients for whom a change from intravenous to oral vitamin d administration is appropriate.


Eligibility criteria:
inclusion criteria: * the subject must be receiving hemodialysis three times per week for a minimum of six months. * the subject must have been receiving hectorol injection for a minimum of 3 months. the subject must have been on a stable dose regimen, three times per week administration for a minimum of four weeks. * the central laboratory assessment must be within the following ranges: serum ipth between 150-600 pg/ml, inclusive; corrected calcium \< 10.0 mg/dl; phosphorus \< 7.0 mg/dl. exclusion criteria: * in the opinion of the investigator, the subject currently has poorly controlled diabetes mellitus, poorly controlled hypertension, active vasculitis, hiv infection, or any other clinically significant, unstable medical condition. * abnormal liver function as measured by alt/ast greater than two times the upper limit of normal (uln). * the subject currently has malabsorption, severe chronic diarrhea, or ileostomy. * any evidence of active malignancy except for basal cell carcinoma of the skin. a history of malignancy is not an exclusion. * current use of aluminum or magnesium based binders.

Keywords: secondary hyperparathyroidism hectorol® (doxercalciferol capsules) hectorol® (doxercalciferol injection)
nutritional counseling associated with the ingestion of oat bran in hypercholesterolemic subjects

Conditions: Dietary Modification

Summary: dyslipidemia is among the risk factors for cardiovascular diseases (cvd). is's due to genetic and / or environmental factors such as inadequate dietary pattern. the occurrence of adverse events with statins, added to recent questions about their benefits on hard outcomes, opens a gap for the importance of seeking other forms of treatment of dyslipidemia, particularly in patients for secondary prevention. the consumption of oat bran, beta-glucan source of dietary fibers with supposed action in reducing the absorption of exogenous cholesterol and the endogenous synthesis of it, and source of avenanthramides, phytochemical compounds with alleged antioxidant in lipid membranes, can be effective strategy for secondary prevention of atherosclerotic disease.

objectives: to evaluate the effect of nutritional counseling associated with the consumption of oat bran (40g per day) in lowering cholesterol, glucose profile and anthropometric parameters of subjects in secondary prevention, evaluate the quality of the diet and the intake of processed foods and ingredients added. methods: a randomized block, double-blind, placebo-controlled trial lasting 90 days. inclusion criteria: individuals aged greater than 20 years, both genders, with ldl-c equal or higher than 130mg/dl fasting lipemia. eligible individuals were considered using oral lipid-lowering, since the dose reported in the early nutritional intervention was maintained during the study. exclusion criteria: patients requiring reduction in daily fluid intake, supplement use in dietary fiber and gestation / lactation. data collected: gender; age; education; drugs; body mass (bm), height, body mass index (bmi), waist circumference (wc), neck circumference (nc); blood pressure; dietary surveys, total cholesterol (tc), ldl-c, hdl-cholesterol (hdl-c), triglycerides (tg), fasting glucose (glu), fasting insulin (ins), homa-ir and quick. the diet quality was evaluated at baseline and end of study through the diet quality index revised (iqd-r). the sample size calculation was performed from a pilot study. it came to the need for 63 subjects for each group, oat bran group (gfav) and placebo group (gpl). the level of statistical significance was 5% (p \<0.05).

Eligibility criteria:
inclusion criteria: * ldl-c equal or higher than 130mg/dl fasting lipemia. exclusion criteria: * patients requiring reduction in daily fluid intake * patients in use of dietary fiber supplements * gestation * lactation

Keywords: nutritional counseling oat bran dyslipidemia cardiovascular disease
this trial, evaluating the long-term safety and tolerability of brivaracetam will provide subjects suffering from epilepsy, who may have benefited from brivaracetam as adjunctive treatment, the opportunity to receive open label brivaracetam treatment

Conditions: Epilepsy

Summary: this trial, evaluating the long-term safety and tolerability of brivaracetam will provide subjects suffering from epilepsy, who may have benefited from brivaracetam as adjunctive treatment, the opportunity to receive open label brivaracetam treatment.

study access was limited to subjects having completed one of the previous brivaracetam (brv) studies: n01193 \[nct00175825\], n01252 \[nct00490035\], n01253 \[nct00464269\], n01254 \[nct00504881\].

Eligibility criteria:
inclusion criteria: * male/ female subjects from 16 years and on. subjects under 18 years may only be included where legally permitted and ethically accepted * subjects with epilepsy who have participated in previous brivaracetam trials which allow access to the present study * subjects for whom the investigator believes a reasonable benefit from the long term administration of brivaracetam may be expected * female subjects without childbearing potential. female subjects with child bearing potential are eligible if they use a medically accepted contraceptive method for the duration of the study * subject/ legally acceptable representative considered as reliable and capable of adhering to the protocol, visit schedule or medication intake according to the judgment of the investigator exclusion criteria: * severe medical, neurological and psychiatric disorders or laboratory values which may have an impact on the safety of the subject * poor compliance with the visit schedule or medication intake in the previous brivaracetam study * pregnant or lactating women * participation in any clinical study of another investigational drug or device during the study

Keywords: brivaracetam epilepsy partial onset seizures open label
a randomized controlled trial of sertraline in paroxysmal arterial hypertension

Conditions: Hypertension

Summary: there is currently no established treatment for paroxysmal hypertension, but selective serotonin reuptake inhibitors showed good effect in previous reports. this double-blind, placebo controlled, prospective multicenter clinical trial will assess the efficacy of sertraline on cessation or reduction of symptoms of paroxysmal arterial hypertension. 136 patients with documented hypertensive paroxysms with abrupt elevations of blood pressure and distressful physical symptoms will be randomized in a 1:1 ratio to receive sertraline, 50 mg daily, or matching placebo as an add-on to their chronic medication. effect of the treatment on patient symptoms, office and ambulatory blood pressure and side effects will be evaluated after 3 months. if proven effective, sertraline might become a standard treatment for this condition.


Eligibility criteria:
inclusion criteria: study will enroll adult patients (age \>18 years) with hypertensive paroxysms during the past 6 months (preferably during the past 6 weeks) - abrupt elevations of systolic blood pressure (bp) ≥20% compared to previous measured systolic bp value before paroxysm, or ≥20% compared to mean systolic bp on 24-hour ambulatory blood pressure monitoring (abpm), or ≥20% compared to measured office systolic bp, documented by a clinician or home blood pressure monitor, requiring physician or emergency room visit or the use of any rescue antihypertensive medication. hypertensive paroxysms may be accompanied by abrupt onset of one or more distressful physical symptoms, such as headache, chest pain, dizziness, nausea, palpitations, flushing, and diaphoresis. exclusion criteria: pregnancy or breastfeeding, hypersensitivity to sertraline (zoloft®) or of the the components of this drug. current use of sertraline or any other selective serotonin reuptake inhibitor (ssri), mono-amin oxidase (mao) inhibitors, selegiline, moclobemide, linezolide, pimozide. current use of other serotoninergic drugs (eg. tryptofane, triptane and other 5-ht agonists), tramadol or dopamine antagonists (including antipsychotics).

Keywords: paroxysmal hypertension pseudopheochromocytoma
effect of nurse-led education on health, quality of life and sexual health

Conditions: Abdominal Aortic Aneurysms (AAA)

Summary: the main hypothesis is that a nurse-led education provided to patients who received endovascular treatment due to enlarged abdominal aorta would present a difference in perceived health, quality of life and sexual health.

a longitudinal, prospective single-centre randomized control trial to evaluate the effects of a nurse-led educational intervention for patients undergoing endovascular intervention for abdominal aortic aneurysm.

Eligibility criteria:
inclusion criteria: * patients who received endovascular treatment for abdominal aortic aneurysm. * patients who could understand and communicate in swedish. exclusion criteria: * cognitive impairment or language impairment that prevents communication and informed consent. * patients who did not receive endovascular treatment.
the role of chest electrical impedance tomography in the pediatric ventilator weaning

Conditions: Ventilator Weaning; Child; Spontaneous Breathing Trial; Electrical Impedance Tomography

Summary: to correlate the data obtained by electrical impedance tomography (eit) during the spontaneous breathing trials (sbt) on a t-piece, in children, with failure in the trial and extubation failure. observe if the eit monitoring will be able to detect the children that will fail earlier than the sbt performed alone. method: a cross-sectional, prospective study to explore the potential benefits of monitoring with eit during weaning.

early and successful extubation is sometimes a difficult combination in children, since the criteria for suggesting it are often subjective and poorly defined. electrical impedance tomography (eit) has been developed and used clinically for more than 30 years. interest in this technology arose from the need to monitor ventilation and pulmonary perfusion at the bedside. because it is a non-invasive and non-radiation technology, eit is very promising in the pediatric population. objectives: to correlate the data obtained by the eit during the spontaneous breathing trials (sbt) on a t-piece with failure in the trial and extubation failure and to observe if the eit is able to detect the children that will fail earlier than the sbt performed alone. method: a cross-sectional, prospective study to explore the potential benefits of monitoring with eit during weaning. qualitative characteristics will be described using absolute and relative frequencies and the quantitative characteristics will be described using summary measures (mean, standard deviation, median, minimum and maximum). bivariate and later multiple logistic regression analyzes will be performed to evaluate the influence of characteristics assessed on weaning failure, mainly the reduction in functional residual capacity during and after the weaning trial. for the analysis will be used the software ibm-spss for windows version 20.0 and tabulation of the data will be used microsoft excel 2010 software. the tests will be performed with significance level of 5%.

Eligibility criteria:
inclusion criteria: children who are on mechanical ventilation for a period of more than 24 hours, between 28 days of age and 15 years, who are admitted to the pediatric intensive care unit (icu) of the children's institute in brazil exclusion criteria: * upper airway obstruction * diaphragmatic hernia or diaphragmatic paralysis * chronic use of mechanical ventilation * cyanogenic congenital heart disease * primary pulmonary hypertension * neuromuscular disease * tracheostomy

Keywords: ventilator weaning child electrical impedance tomography respiration, artificial intensive care units
safety and efficacy of the buprenorphine transdermal delivery system in subjects with osteoarthritis pain.

Conditions: Osteoarthritis

Summary: the objective of this study is to assess the safety and efficacy of the buprenorphine transdermal system (5, 10, and 20 mg) in comparison to placebo transdermal system in subjects with osteoarthritis pain. the double-blind treatment intervention duration is 28 days.

buprenorphine is a synthetic opioid analgesic with over twenty-five years of international clinical experience indicating it to be safe and effective in a variety of therapeutic situations for the relief of moderate to severe pain. transdermal systems may offer advantages over currently indicated oral products including ease and convenience of use, improved compliance, possible reduction in patient care, and prolonged and consistent delivery of drug.

Eligibility criteria:
inclusion criteria: * documented history and/or radiologic evidence of chronic osteoarthritis of the hip or knee. * receiving opioid therapy for osteoarthritis-related pain within the past year or have experienced pain that was inadequately controlled with a full standard dose of nsaids. exclusion criteria: * receiving opioids at an average daily dose of greater than 90 mg of oral morphine equivalents or patients receiving more than 12 tablets or capsules per day of short-acting opioid-containing products * scheduled to have surgery (including dental) during the study period that involved the use of pre- and/or postoperative analgesics or anesthetics. other protocol-specific exclusion/inclusion criteria may apply.

Keywords: osteoarthritis chronic pain opioid transdermal